Contrasting Hyperion DeFi (NASDAQ:HYPD) and KindlyMD (NASDAQ:NAKA)

KindlyMD (NASDAQ:NAKA) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Volatility and Risk

KindlyMD has a beta of 16.03, indicating that its stock price is 1,503% more volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.74, indicating that its stock price is 174% more volatile than the S&P 500.

Profitability

This table compares KindlyMD and Hyperion DeFi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
KindlyMD	-1,067.93%	-63.45%	-41.04%
Hyperion DeFi	416.56%	-11.62%	-9.96%

Analyst Ratings

This is a summary of current ratings and recommmendations for KindlyMD and Hyperion DeFi, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KindlyMD	1	0	3	0	2.50
Hyperion DeFi	1	1	2	0	2.25

KindlyMD presently has a consensus price target of $20.00, indicating a potential upside of 241.30%. Hyperion DeFi has a consensus price target of $9.82, indicating a potential upside of 205.12%. Given KindlyMD’s stronger consensus rating and higher possible upside, equities research analysts plainly believe KindlyMD is more favorable than Hyperion DeFi.

Institutional & Insider Ownership

25.8% of Hyperion DeFi shares are held by institutional investors. 24.1% of KindlyMD shares are held by company insiders. Comparatively, 7.5% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares KindlyMD and Hyperion DeFi”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KindlyMD	$1.82 million	59.08	-$52.23 million	($35.85)	-0.16
Hyperion DeFi	$810,000.00	61.78	-$45.31 million	($6.53)	-0.49

Hyperion DeFi has lower revenue, but higher earnings than KindlyMD. Hyperion DeFi is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks.

About KindlyMD

Kindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.